BioCardia, Inc.
BCDA
Rank in Stocks
#27766
BioCardia, Inc. is a pioneering clinical-stage company dedicated to... BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Share Price
$0.9026
Last synced: 2026-11-09
Market Cap
$13.66M
Change (1 day)
6.19%
Change (1 year)
-32.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioCardia, Inc. (BCDA)
Category
Healthcare
EPS for BioCardia, Inc. (BCDA)
EPS as of June 2026 TTM: $-0.76
According to BioCardia, Inc.'s latest financial reports, its current EPS (TTM) is $-0.76. At the end of 2025 the company had an EPS of $-1.23, an increase over its 2024 EPS of $-2.90.
EPS history for BioCardia, Inc. from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.76 | -38.21% |
| 2025 | $-1.23 | -57.59% |
| 2024 | $-2.90 | -64.59% |
| 2023 | $-8.19 | -18.51% |
| 2022 | $-10.05 | -10.19% |
| 2021 | $-11.19 | -49.59% |
| 2020 | $-22.20 | -43.30% |
| 2019 | $-39.15 | -19.77% |
| 2018 | $-48.80 | 12.18% |
| 2017 | $-43.50 | -73.85% |
| 2016 | $-166.33 | -697.02% |
| 2015 | $27.86 | 35.90% |
| 2014 | $20.50 | 15,669.23% |
| 2013 | $0.13 | -99.55% |
| 2012 | $28.61 | -55.85% |
| 2011 | $64.80 | -106.00% |
| 2010 | $-1.08K | 104.18% |
| 2009 | $-528.72 | -28.78% |
| 2008 | $-742.35 | 2,030.74% |
| 2007 | $-34.84 | 244.95% |
| 2006 | $-10.10 | -89.74% |
| 2005 | $-98.42 | 6.54% |
| 2004 | $-92.38 | 50.70% |
| 2003 | $-61.30 | -60.93% |
| 2002 | $-156.91 | -42.97% |
| 2001 | $-275.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,160.53% |
US
|
|
| $-7.07 | 830.26% |
US
|
|
| $-5.29 | 596.05% |
AU
|
|
| $12.88 | -1,794.75% |
BE
|
|
| $21.56 | -2,936.84% |
NL
|
Questions about BioCardia, Inc.'s earnings per share (EPS)
What is BioCardia, Inc.'s earnings per share (EPS)?
BioCardia, Inc.'s earnings per share (EPS) over the last twelve months is $-0.76, as of Jun 2026.
What was BioCardia, Inc.'s earnings per share (EPS) in 2025?
In 2025, BioCardia, Inc.'s earnings per share (EPS) was $-1.23, compared with $-2.90 in 2024.
How has BioCardia, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, BioCardia, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.23) and lowest in 2020 ($-22.20).
How does BioCardia, Inc.'s earnings per share (EPS) compare with similar companies?
BioCardia, Inc.'s earnings per share (EPS) ($-0.76) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.